After Oppenheimer and Roth Capital gave Epizyme (NASDAQ: EPZM) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Epizyme today and set a price target of $25. The company’s shares closed on Friday at $14.95.
Fein noted:
“We believe Taz data in patients with EZH2- activating mutations presented at the 23rd EHA Congress last week met our expectations, and should be approvable from a regulatory standpoint.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.2% and a 51.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $24.38, representing a 63.1% upside.
In a report issued on June 11, Roth Capital also maintained a Buy rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $21.40 and a one-year low of $11.15. Currently, Epizyme has an average volume of 415.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Develops therapeutics for the treatment of patients with genetically defined cancers
